NCT05818540

Brief Summary

The Randomized Controlled Trial of Bleep DreamPort-Eclipse Study is a two-arm, randomized, prospective, non-blinded study to assess the effectiveness of the novel CPAP human interface design to improve leak, AHI, and pressure compared to a traditional nasal mask.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
173

participants targeted

Target at P75+ for not_applicable

Timeline
Completed

Started Apr 2023

Shorter than P25 for not_applicable

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

April 4, 2023

Completed
13 days until next milestone

Study Start

First participant enrolled

April 17, 2023

Completed
2 days until next milestone

First Posted

Study publicly available on registry

April 19, 2023

Completed
8 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 29, 2023

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

December 29, 2023

Completed
1.9 years until next milestone

Results Posted

Study results publicly available

November 10, 2025

Completed
Last Updated

November 10, 2025

Status Verified

October 1, 2025

Enrollment Period

9 months

First QC Date

April 4, 2023

Results QC Date

March 13, 2025

Last Update Submit

October 24, 2025

Conditions

Outcome Measures

Primary Outcomes (3)

  • Apnea-Hypopnea Index (AHI)

    AHI recorded from the software built-in algorithm. The Apnea-Hypopnea Index or Apnoea-Hypopnoea Index (AHI) is an index used to indicate the severity of sleep apnea. It is represented by the number of apnea and hypopnea events per hour of sleep. The apneas (pauses in breathing) must last for at least 10 seconds and be associated with a decrease in blood oxygenation.

    60 days

  • Leak

    Data were captured from the device in L/min at 60 days. Leak is how much flow in L exits the mask while the patient wears it each min. It is recorded through proprietary algorithm undisclosed to the public by the device

    60 days

  • CPAP Device Pressure (P95)

    Therapeutic positive pressure (in cmH2O) that the device administer for 95% of the night. It is recorded through proprietary algorithm undisclosed to the public by the device.

    60 days

Secondary Outcomes (2)

  • Participant Satisfaction With the Mask Choice

    60 days

  • Percentage of Participants Who Could Tolerate the Mask Well (Mask Tolerability)

    60 days

Study Arms (2)

Eclipse novel mask

EXPERIMENTAL

Human subjects will use the Eclipse CPAP interface for 60 days for a total of 6 hours per night.

Device: Eclipse novel CPAP mask

Traditional CPAP mask

ACTIVE COMPARATOR

Human subjects will use the ResMed P-10 CPAP interface for 60 days for a total of 6 hours per night.

Device: ResMed P-10 mask

Interventions

Participants will wear the mask for 6 hours a night for 60 days.

Eclipse novel mask

Participants will wear the mask for 6 hours a night for 60 days.

Traditional CPAP mask

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Male or female ≥18 years old who are impacted by obstructive sleep apnea and currently are familiar with a CPAP device

You may not qualify if:

  • Any medical or behavioral conditions that would compromise subject safety
  • Under the age of 18 years old

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Sleep Centers of Middle Tennessee

Murfreesboro, Tennessee, 37129, United States

Location

MeSH Terms

Conditions

Sleep Apnea, Obstructive

Condition Hierarchy (Ancestors)

Sleep Apnea SyndromesApneaRespiration DisordersRespiratory Tract DiseasesSleep Disorders, IntrinsicDyssomniasSleep Wake DisordersNervous System Diseases

Results Point of Contact

Title
Stuart Heathington
Organization
Bleep, LLC

Study Officials

  • Stuart Heatherington

    Bleep, LLC

    PRINCIPAL INVESTIGATOR

Publication Agreements

PI is Sponsor Employee
No
Restrictive Agreement
No

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
NONE
Masking Details
Data collected will be deidentified upon collection - surveys and assessment forms will be labelled with a numerical identifier.
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
INDUSTRY
Responsible Party
SPONSOR

Study Record Dates

First Submitted

April 4, 2023

First Posted

April 19, 2023

Study Start

April 17, 2023

Primary Completion

December 29, 2023

Study Completion

December 29, 2023

Last Updated

November 10, 2025

Results First Posted

November 10, 2025

Record last verified: 2025-10

Data Sharing

IPD Sharing
Will share

Data collected through surveys will be available upon request to the principal investigator. Data requested will be de-identified. Only de-identified data will be made available. Only survey responses and the investigators' observational notes, also deidentified, will be shared. No PHI will be shared. Aggregated participant demographic data will be shared.

Shared Documents
STUDY PROTOCOL, SAP, CSR
Time Frame
Data will become available 4 years after the study completion.
Access Criteria
Requests will be made in writing, to the PI, at stuart@bleepsleep.com. Requests should include the reason for the request, how the data is intended to be used, and additional information may be requested. Data will be shared with credentialed, licensed, or otherwise verifiable researchers/investigators for research purposes only.

Locations